Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

NCT04447911 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

172

Enrollment

OTHER

Sponsor class

Conditions

Hyponatremia
SIADH
Liver Failure
Kidney Failure

Interventions

DRUG: Empagliflozin 25 MG
DRUG: Placebo

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]
[object Object]